Cargando…
Nucleocapsid protein of SARS‐CoV‐2 is a potential target for developing new generation of vaccine
BACKGROUND: SARS‐CoV‐2 has spread worldwide causing more than 400 million people with virus infections since early 2020. Currently, the existing vaccines targeting the spike glycoprotein (S protein) of SARS‐CoV‐2 are facing great challenge from the infection of SARS‐CoV‐2 virus and its multiple S pr...
Autores principales: | Feng, Weixu, Xiang, Yunru, Wu, Lianpeng, Chen, Zhuo, Li, Qingfeng, Chen, Jun, Guo, Yanru, Xia, Dandan, Chen, Na, Zhang, Lifang, Zhu, Shanli, Zhao, Kong‐Nan |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9169192/ https://www.ncbi.nlm.nih.gov/pubmed/35527696 http://dx.doi.org/10.1002/jcla.24479 |
Ejemplares similares
-
Novel Affibody Molecules Specifically Bind to SARS-CoV-2 Spike Protein and Efficiently Neutralize Delta and Omicron Variants
por: Du, Wangqi, et al.
Publicado: (2022) -
Biochemical characterization of SARS-CoV-2 nucleocapsid protein
por: Zeng, Weihong, et al.
Publicado: (2020) -
Corrigendum to “Biochemical characterization of SARS-CoV-2 nucleocapsid protein”
por: Zeng, Weihong, et al.
Publicado: (2022) -
Antibody detection of SARS-CoV spike and nucleocapsid protein
por: Chang, Mau-Sun, et al.
Publicado: (2004) -
The Nucleocapsid Protein of SARS–CoV-2: a Target for Vaccine Development
por: Dutta, Noton K., et al.
Publicado: (2020)